Inebilizumab for immunoglobulin G4-related disease

Inebilizumab is in development for the treatment of immunoglobulin G4-related disease (IgG4-RD). Immunoglobulin G4 is a type of antibody, which are proteins essential to the immune system as they can bind to unwanted substances within the body and eliminate them. In IgG4-RD these antibodies do not function correctly, which leads to inflammation of organs. Prolonged inflammation of an organ can damage and/or reduce that organ’s ability to perform its function. Although this may not be noticed immediately, the disease can damage one or more organs even whilst the individual is feeling healthy. Symptoms depend on the organs affected, but commonly include abdominal pain, weight loss, headaches, dysfunction of the cranial nerves, bulging of one or both eyes and painless jaundice (a yellow tint to the skin).